NeuroDiscovery closes IPO
Friday, 12 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) has closed its $1.5 million IPO and completed its acquisition of UK-based NeuroSolutions.
NeuroDiscovery offered 7.5 million shares at an issue price of AUD$0.20 each to raise the $1.5 million. NeuroSolutions - which has a mature pipeline of programs for the treatment of pain - is expected to commence Phase I and II clinical trials in the next 18 months.
NeuroDiscovery expects to list on the ASX on Monday 15 August.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
